Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Peptostreptococcus" patented technology

Peptostreptococcus is a genus of anaerobic, Gram-positive, non-spore forming bacteria. The cells are small, spherical, and can occur in short chains, in pairs or individually. They typically move using cilia. Peptostreptococcus are slow-growing bacteria with increasing resistance to antimicrobial drugs. Peptostreptococcus is a normal inhabitant of the healthy lower reproductive tract of women.

A marker combination related to postoperative prognosis of colorectal cancer and application and prediction system thereof

PendingCN122235339AComponent separationEnsemble learningPeptostreptococcusArginine
This invention belongs to the fields of bioinformatics and medical testing technology, specifically relating to a combination of biomarkers related to the postoperative prognosis of colorectal cancer and their application and prediction system. This invention, through 16S rRNA gene sequencing of tumor mucosal samples from colorectal cancer patients, combined with long-term postoperative follow-up data and screening, found that *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella* are closely related to postoperative recurrence of colorectal cancer, with an AUC of 0.81 for assessing postoperative recurrence. Based on this, this invention conducts non-targeted metabolomics analysis, finding that combining alanine glutamate, putrescine, arginine, histidine, and sebacic acid with the above microbial biomarkers can improve the AUC to 0.91, significantly enhancing accuracy, specificity, and precision. This enables prognostic stratification of recurrence-free survival in colorectal cancer patients, demonstrating higher predictive efficacy and stability.
Owner:NANKAI UNIV +1

A cervical cancer plasma circulating microorganism marker combination, reagent, kit, risk assessment model and application thereof

ActiveCN120924694BHealth-index calculationMicrobiological testing/measurementPeptostreptococcusStreptococcus spp
The application discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the technical field of liquid biopsy and microbiome. The cervical cancer plasma circulating microbial marker combination comprises Prevotella, Sneathia, Chlamydia trachomatis, Peptostreptococcus, Fusobacterium, Campylobacter and Haemophilus. The cervical cancer plasma circulating microbial marker combination is used for verifying cervical cancer patients and healthy people, and the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, which indicates that the cervical cancer plasma circulating microbial marker combination can effectively distinguish cervical cancer patients from healthy people, is suitable for early screening of cervical cancer, and has significant clinical screening application value.
Owner:BEIJING XUTENG GENE TECHNOLOGY CO LTD